HOUSTON, Sept. 28, 2023 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immunotherapies, today announced the first patient has been dosed in the company's Phase 1a/1b clinical trial of its lead candidate, IMGS-001, at The University of Texas MD Anderson Cancer Center in Houston, Texas. IMGS-001 is a dual-specific programmed cell death 1 ligand 1 (PD-L1)/programmed cell death 1 ligand 2 (PD-L2) antibody engineered with cytotoxic function designed to treat cold, immune-excluded tumors, which are resistant to existing immunotherapy.
HOUSTON, June 27, 2023 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immune therapies, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund plans to invest $4.5 million to support the Phase 1a/1b clinical trial of ImmunoGenesis' lead candidate, IMGS-001. IMGS-001 is a dual-specific PD-L1/PD-L2 antibody designed to treat immune-excluded tumors, which are resistant to existing immunotherapy. The investment will support the portion of the IMGS-001 Phase 1a/1b multi-site clinical trial being conducted at MD Anderson. It coincides with ImmunoGenesis' Series A financing, which is expected to close in the third quarter.
HOUSTON, Nov. 3, 2022 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immune therapies, today announced that two poster presentations on its lead development program, IMGS-001, will be presented at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022), November 8-12, 2022, in Boston, MA. The posters will be available on the ImmunoGenesis website following the conference.
Agenus Inc., an immuno-oncology company with a pipeline of therapeutics designed to activate the immune response to cancers and infections, has entered into three new clinical collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis, doubling its current number of clinical collaborations.
HOUSTON, Dec. 14, 2021 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immune therapies, announced the appointment of seasoned industry veteran Charles Schweizer, PhD, as Senior Vice President of Clinical Development. Dr. Schweizer delivers more than 25 years of oncology clinical product development, regulatory, and operations experience across pharma/biotech and contract research organizations (CROs), including most recently as Therapeutic Area Head of Oncology at GSK. In his new ImmunoGenesis role, he will drive clinical development strategy and operational execution as the company prepares to initiate multiple clinical trials in 2022.
HOUSTON, Nov. 15, 2021n/PRNewswire/ -- ImmunoGenesis, a clinical-stage biotechnology company ndeveloping science-driven immune therapies, announced today that npreclinical data from its lead development programs were presented in nsix scientific posters at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021), which was held November 10-14, 2021, in Washington, DC. The pr
HOUSTON, Nov. 3, 2021 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immune therapies, today announced the acceptance of six poster presentations on its lead development programs at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021), which will be held November 10-14, 2021, in Washington, DC. Additional meeting information can be found on the SITC website.
ImmunoGenesis, a clinical-stage biotechnology company developing immune therapies, has appointed seasoned industry veterans to key roles to support the expansion of the company's R&D, clinical and business development activities. ImmunoGenesis also opened a research laboratory in JLABS @ TMC in Houston, TX, to facilitate critical translational research for its drug development programs.